We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byTerrance Cressy
Modified over 2 years ago
© Safeguarding public health Expert Group on Innovation in the Regulation of Healthcare products Adaptive Licencing workshop at the Wellcome Trust October 15, 2012
Slide 2 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Expert Group work programme Early Access work International/comparative experience Clinical trial activity in the UK Defining the challenge in regulatory innovation -including Adaptive Licensing and developments in PV Mapping projects and initiatives -UK and US (Newdigs) Related initiatives -Advanced manufacturing regulation
Slide 3 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Developments and Action Information on flexibilities in existing licensing routes -On internet and with representative bodies -MHRA Paper Early access consultation EU proposal on Clinical Trials -Wide range of other work under the Growth Review Adaptive licensing -Initiatives and thinking on adaptive licensing -Key questions and scoping -A pilot programme of activity on adaptive licensing by Dec 2012
© Safeguarding public health Early Access
Slide 5 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Early Access Scope of the scheme -New medicines in areas of unmet need -Benefit:risk profile of the medicine must be positive -Availability restricted to predefined patient population Characteristics of the scheme -MHRA provides scientific opinion on the medicine -Medicine could be available for around 1 yr before licence granted The medicine remains unlicensed -No advertising permitted
Slide 6 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Early Access Eligible patients -Patients of any age (including children), no CT participants Eligible drugs -Restricted to any therapeutic area with un-met need Safety monitoring requirements -ADR reporting requirements will apply, additional monitoring tbd on a case by case basis
Slide 7 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Early Access Pricing -Freedom of pricing for producers of EA drugs but -NHS Trusts decide on purchase of medicine (lower cost encourages NHS uptake) Patient consent and liability issues -‘Active’ patient consent -Effective information dissemination -Manufacturer remains liable for supplying defective product Additional criteria -Benefit to UK economy -NHS funding for the medicines must be cost effective
© Safeguarding public health Adaptive Licencing
Slide 9 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Adaptive Licencing: EU / UK? Existing Legislation or not? If a UK scheme -Unlicensed use under the professional/legal responsibility of prescriber -Product for un-met need -Essentially a variant of Early Access If EU scheme -Centralised product; EU regulation applies -EMA, not UK coordinates licencing decision -European Commission will be the licensing authority Existing regulation or not? -Essentially a matter of time-frame
Slide 10 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Adaptive Licencing 3 levels of activity / tripartite structure -Level 1: EU (EMA, CHMP discussions) -Level 2: HMG/MHRA -Level 3: Industry / third sector Critical role for EU -EU licensing process -European Commission will be the licensing authority Considerable opportunities for action under current rules -Alternative means long timeframes Industry must come up with a product/asset -None identified so far – on either side of the Atlantic Merit in both retrospective and prospective work
Slide 11 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Adaptive Licencing Critical issues in regulatory decision making (risk/benefit calculation) -Evidential levels to apply -Role of RCTs – and use and interpretation of observational data Industry policy / public health policy -Industry financial/business risks / interests? Patient / professional / media understanding Wider system challenges: -Pricing / VBP -Company decisions / management of their development pipelines and processes Pilot project by end 2012
Slide 12 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © An “asset” or a product Likely characteristics: -break/-through product for as yet un-met need -Perhaps not as “open and shut” as Glivec, but not far off -Likely to be for small(er) patient population ·but not necessarily -For some of the AL ideas, possibly a product with multiple potential uses -[Probably] something with an identified patient group ·Informed consent etc
Slide 13 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Adaptive Licencing - Forward Look EU / EMA -Management Board discussion: March CHMP and other EMA committees -Commission HMG/MHRA -Defining the pilot, and the problem(s) it is to solve -Licensing routes available -Toolbox of options -Structures and roles -Governance framework needed -Relation and link with industry/third sector support project
© Safeguarding public health Conclusions of Expert Group meeting October : focused on Adaptive Licensing
Slide 15 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Conclusions of EG meeting, Oct 9 AL to be positioned at EU level within current legislative framework Tripartite project structure makes sense Practical programme of activity by the end of the year Need to be clear about what questions we are trying to solve Regulation, Clinical Trials, purchasing and R&D strategies within companies all relevant
Slide 16 Oct 15, 2012 Adaptive Licencing Workshop at the Wellcome Trust © Work and steps ahead Commissioned papers: -Pharmacovigilance Further consideration: -EMA level work on regulatory challenge of AL -Capacity of CPRD wrt AL Pilot project for the end of the year -Retrospective and prospective activity -Identification of potential products
Commissioning Support Lead Provider Framework Agreement Provisional statement on our approach This short discussion document aims to: Provide an update.
EURELECTRIC WG Retail Markets Presentation for ERGEG Customer Focus Group Helsinki, 11 October 2005.
Six Countries Programme – Innovation and Procurement Wednesday 16 November 2005 Margaret Horton Head of Research and Innovation The UK Approach to Procurement.
1 6 th European Patients Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Zoe Whale / Lynette Lane GCP Facilitators, NISCHR CRC Good Clinical Practice in Research Clinical Trial Regulations.
Presentation title: 32pt Arial Regular, black Recommended maximum length: 1 line Quality is everything! Tricia Ellis AWHILES Conference 2 nd July 2008.
An agency of the European Union Enpr-EMA European Network of Paediatric Research at the European Medicines Agency Background information Irmgard Eichler,
© Crown copyright 2005 Safeguarding public health Review of Unlicensed Medicines MHRA meetings with interested parties March 2011.
EURADWASTE 29 March 2004 LOCAL COMMUNITIES IN NUCLEAR WASTE MANAGEMENT THE COWAM EUROPEAN PROJECT EURADWASTE, 29 March 2004.
11 This is a very brief overview of the proposed Structures in the Health and Social Care Bill 2011: Commissioning for Patients Regulating Healthcare providers.
October 2013 A fresh start for the regulation and inspection of adult social care.
Overview of Risk management: A EU perspective Lincoln Tsang May 2008.
This project has been funded with support from the European Commission under Seventh Framework Programme (FP7) Innovative PROcurement techniques to support.
FP7-ICT-2013 Pre-Commercial Procurement (PCP) Lieve Bos (lieve.bos AT ec.europa.eu) European Commission DG CONNECT F2 unit (Innovation)
Electricity Balancing Framework Guidelines ACER Workshop Ljubljana, 24 October 2011.
EU-US Regulatory Cooperation Approaches and Experiences Jan E. Frydman Head of Unit for International Regulatory Agreements and Toy Safety Directorate.
Global Animal Health Initiative: The way forward Washington, 9 October 2007 OIE economic studies part III: Supporting insurance of disease losses by Civic.
Summary of Future Shape Business Case The Future Shape business case proposes a fundamental change in the way the County Council operates. On Monday 24.
Mike Kreuzer OBE Executive Director, Technical and Regulatory Medical Device Regulation - the next twenty years ?-
Project funded by The European Union Government of the Republic of Serbia European Integration Office All presentations are available on the PPF5 website:
The Implementation Structure DG AGRI, October 2005 EU Rural Development.
Manage an IT Project. Aim This presentation is prepared to support and give a general overview of the ‘How to Manage and IT Project’ Guide and should.
1 Monday 14 March 2011 Windhoek, Namibia Leona Mentz ITU Expert Validation Workshop Session 4.2: Presentation of the Toolkit.
21/02/20141 Informal Consultation on Nomenclatures for Medical Devices World Health Organization, Headquarters March 2011 Geneva, Switzerland Martin.
Quality Accounts: Stakeholder Engagement. Introduction.
Technical Market Access and Quality Infrastructure Part 4: Standardization and Innovation Beijing Quality Partnerships LLC.
Work programme 2009 – Info Day European Commission – DG Enterprise & Industry E-M. Engdahl Information Day 16th September 2009 Brussels Kristien Van Goey.
Operating your collaboration Why would you use it?How does it work? Operating a collaboration, collaborative governance or federation is challenging. Schools.
Advertising in the EU Alcohol Strategy Dr Jonathan Back Unit 02 – Strategy and Analysis Directorate General for Health and Consumers European Commission.
PRESENTATION Monitor’s current and future roles: a gap analysis Monitor’s current and future roles: a gap analysis Patrick Fraher Senior Policy Advisor.
© 2016 SlidePlayer.com Inc. All rights reserved.